Is non-adherence to blame? [1]

Inflammatory Bowel Diseases

Volumn 11, Issue 7, 2005, Pages 705-

  Kane, Sunanda ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

DISEASE COURSE; DRUG EFFICACY; HUMAN; LETTER; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE; ULCERATIVE COLITIS;

EID: 21844477621     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000161306.81198.d4     Document Type: Letter

References (2)

1. Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis. 2004;10:731-736.
2. Kane SV, Cohen RD, Aikens JE, et al. Predictors of non-compliance with mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96:2929-2932.